Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IDPH....Needs to hold here.
I'm in but strickly for the short term.
PSUN downgrade.....short candidate
WFMI....Heading up on earnings.
CRY is going up.....news
From NYPost
"NEW BIN LADEN TAPE CLAIMED IN BRITAIN
By JANE WARDELL Associated Press Writer
LONDON (AP) . A British-based Islamic news agency said Thursday it has a new audio recording of Osama bin Laden in which he predicts he will die as ``a martyr'' this year in an attack against his enemies.
The Al-Ansaar news agency said that the 53-minute tape was allegedly recorded this month and acquired from a seller who advertised over the Internet.
Imran Khan, who runs Birmingham-based agency Al-Ansaar, told The Associated Press that he translated the tape, describing it as poetic with several verses from the Quran.
``In this final year I hurl myself and my steed with my soul at the enemy. Indeed on my demise I will become a martyr,'' the al-Qaida leader purportedly says. "
http://www.nypost.com/apstories/V9481.htm
IDBE....
VANCOUVER, Feb 12, 2003 (Canada NewsWire via COMTEX) --
ID Biomedical announced today that preliminary
data from the most recent clinical study of its FluINsure intranasal, non-
live, influenza vaccine showed positive results with respect to both the
safety and clinical efficacy endpoints of the study. Based on these results,
the Company expects to take the FluINsure vaccine to a field efficacy study
during the 2003 flu season.
In this "challenge" study, volunteers who were pre-selected for low
titers of antibody to the challenge strain (A/Panama/2007/99, an A/H3N2 virus)
were assigned, in a randomized and blinded manner, to three groups: one group
receiving a single dose of FluINsure, one group receiving two doses of
FluINsure, and one group receiving placebo. The study enrolled 75 volunteers,
and of these, 67 were challenged with influenza (8 people either declined to
undergo challenge or were excluded because they had signs of the common cold
and could not be challenged). The clinicians conducting the study evaluated
each individual for a variety of clinical signs of influenza, such as fever,
respiratory illness, and systemic illness.
The results of the study show a clear trend of efficacy from placebo, to
the one-dose, to the two-dose cohort. Among subjects who had been given
placebo, 48% had influenza-like illness (defined by meeting criteria for any
one of upper respiratory illness, lower respiratory illness, fever and/or
other systemic symptoms). In the two-dose group, 19 of 22 volunteers (86%) met
no illness criteria. This represents a 71.4% reduction in illness relative to
placebo, which is statistically significant (p equals 0.043). Furthermore,
FluINsure immunization resulted in complete elimination of all measures of
systemic illness (100% protection against fever, headache, myalgia/arthralgia)
in the two-dose group. In the one-dose group, the percentage of those meeting
no criteria for influenza-like illness was less, and did not attain
significant difference from placebo. However, analysis of a secondary endpoint
reflecting upper respiratory illness severity, showed a statistically
significant downward trend (p (equals 0.013) across both the one- and two-dose
groups, with either active treatment group individually being significantly
lower than placebo. In addition, relative to placebo, there was an approximate
40% reduction in systemic illness (fever, headache, myalgia/arthralgia) in the
one-dose group.
Analysis of all the serum and mucosal antibody responses, as well as
viral shedding data from this trial will be completed in Q2. The Company
expects complete results of the study to be submitted for peer-reviewed
publication later this year.
"There is a very encouraging and clear trend of efficacy. FluINsure
achieved a statistically significant level of protection with the two-dose
regimen. The level of protection achieved in this challenge trial suggests
that FluINsure could be highly efficacious in our planned field study. The
data from the one-dose cohort also participate in the positive trend and,
although not statistically significant in this small study, certainly suggest
the one-dose regimen was immunologically active and modified disease. Thus,
further testing of both regimens is warranted." stated Dr. Louis Fries, ID
Biomedical's Vice President of Clinical and Regulatory Affairs. "Considering
that all the volunteers enrolled had non-immune levels of pre-existing
antibody levels to the challenge stain and received a direct nasal inoculation
with a high-titered virus suspension, these data provide great confidence in
initiating a field study. In the field, of course, one would not expect an
entirely naive population, nor are people likely to be exposed to as stringent
a challenge."
"These results offer the first direct proof that FluINsure can protect
people against influenza - the proof-of-principle was established." stated Dr.
Anthony Holler, ID Biomedical's Chief Executive Officer. "With these positive
findings, it is now prudent to advance FluINsure to a large, field efficacy
study in the upcoming flu season." Holler added that based on the positive
data of this trial and of immunogenicity data from previous trials, the
Company will conduct, in Q2-Q3 of this year, a second challenge study to
demonstrate protection using reduced dose levels and a trial using an advanced
formulation suitable for field studies and for testing in a pediatric
population. Both one and two dose regimens will be evaluated.
NEM....
For years, Barrick Gold Corp.'s (ABX) hedge contracts served the company well when gold was below US$300 an ounce and it was able to sell production at higher-than-market prices. But at the end of September, its hedgebook had a negative mark-to-market value of US$301 million at a spot gold price of US$324 an ounce. An update should be released later Wednesday with the company's fourth-quarter results.
The negative value of most producer hedgebooks became greater in the fourth quarter, as gold prices increased, Canaccord Capital analyst Brian Christie said in a research note this week. He said this should continue to feed negative market sentiment about hedging.
Barrick emphasized plans in 2002 to simplify and reduce its hedgebook and made progress in the last year, Barrick spokesman Vince Borg said. The ability of the company to speed up those changes will depend entirely on the price of gold, he added. For example, in January Barrick sold gold at spot prices due to the run-up in prices and deferred some contracts, Borg said. This shows the flexibility of the hedging program, he said.
As the company's stock price falls relative to its peers, it becomes more difficult for Barrick to acquire other gold companies or properties using its paper, Frank Holmes of U.S. Global Investors Inc. noted. "This is very dangerous for Barrick - it's been the shark, it's been hunting," he said. Senior companies like Barrick and Newmont Mining Corp. (NEM) need to acquire assets to maintain their existing production profile, Holmes said.
While outgoing chief executive Randall Oliphant may be best remembered for Barrick's hedging policies, HSBC Asset Management's Charlie Kim said his legacy should also include the company's growth plan. In September, Oliphant laid out a US$2 billion, four-mine development program which is supposed to see the company's gold output rise to 6.9 million ounces by 2006, at lower costs.
"They've got a very formulated growth plan in terms of production. I think he set the company in the right direction," Kim said.
NEM....
For years, Barrick Gold Corp.'s (ABX) hedge contracts served the company well when gold was below US$300 an ounce and it was able to sell production at higher-than-market prices. But at the end of September, its hedgebook had a negative mark-to-market value of US$301 million at a spot gold price of US$324 an ounce. An update should be released later Wednesday with the company's fourth-quarter results.
The negative value of most producer hedgebooks became greater in the fourth quarter, as gold prices increased, Canaccord Capital analyst Brian Christie said in a research note this week. He said this should continue to feed negative market sentiment about hedging.
Barrick emphasized plans in 2002 to simplify and reduce its hedgebook and made progress in the last year, Barrick spokesman Vince Borg said. The ability of the company to speed up those changes will depend entirely on the price of gold, he added. For example, in January Barrick sold gold at spot prices due to the run-up in prices and deferred some contracts, Borg said. This shows the flexibility of the hedging program, he said.
As the company's stock price falls relative to its peers, it becomes more difficult for Barrick to acquire other gold companies or properties using its paper, Frank Holmes of U.S. Global Investors Inc. noted. "This is very dangerous for Barrick - it's been the shark, it's been hunting," he said. Senior companies like Barrick and Newmont Mining Corp. (NEM) need to acquire assets to maintain their existing production profile, Holmes said.
While outgoing chief executive Randall Oliphant may be best remembered for Barrick's hedging policies, HSBC Asset Management's Charlie Kim said his legacy should also include the company's growth plan. In September, Oliphant laid out a US$2 billion, four-mine development program which is supposed to see the company's gold output rise to 6.9 million ounces by 2006, at lower costs.
"They've got a very formulated growth plan in terms of production. I think he set the company in the right direction," Kim said.
We shall seee....I'm just going to sit on my short and wait for the wind.
RMBS looking tired here. Today could be the day it breaks down thru $13.11..
GRMN near a day high now on big volume.
DCLK.....Day high now
VIP....Day high
DCLK....Interesting
TEVA....Day low
A few movers...
GENERAL MOTORS (GM)
Banc of America cut its rating on the stock to sell from
neutral, saying the auto maker will have to cut its
dividend over the medium term.
Price: $34.00
Net Change: -$1.55
% Change: 4.36% Loss
Volume: 1.6M Shares
... ... ...
PEC SOLUTIONS (PECS)
Expects first-quarter earnings and revenue to miss Wall
Street's targets. Sees earnings per share of 17 cents to
18 cents, on revenue of $48 million to $49 million,
compared with analysts' average estimate of 20 cents a
share on revenue of $54.1 million. Net income in the
fourth quarter rose to 20 cents a share from 11 cents a
share a year earlier.
Price: $19.87
Net Change: -$8.93
% Change: 31.01% Loss
Volume: 2.5M Shares
... ... ...
EL PASO CORP (EP)
Moody's Investors Service downgraded its debt ratings on
El Paso five notches to a highly speculative Caa1 from
Ba2; also, the company said its chairman and chief
executive officer will step down.
Price: $4.08
Net Change: -$0.64
% Change: 13.56% Loss
Volume: 3.3M Shares
... ... ...
MESA AIR GROUP (MESA)
Credit Suisse First Boston upgraded its investment
rating on the stock to outperform from neutral.
Price: $4.67
Net Change: $0.45
% Change: 10.55% Gain
Volume: 127,320 Shares
... ... ...
SANGSTAT (SANG)
Expects earnings of 35 cents to 45 cents a share in
2003, in contrast with analysts, who expect the company
to earn 52 cents a share. Fourth-quarter net income rose
to 5 cents a share from 2 cents.
Price: $7.83
Net Change: -$2.28
% Change: 22.55% Loss
Volume: 770,196 Shares
... ... ...
JAKKS PACIFIC (JAKK)
Fourth-quarter earnings of 25 cents a share, excluding
credits, missed the Thomson First Call analyst estimate
by 7 cents.
Price: $10.64
Net Change: -$1.76
% Change: 14.19% Loss
Volume: 194,914 Shares
... ... ...
SURMODICS INC (SRDX)
Announced the departure of its chief financial officer
and said its president has decided to retire, but
reaffirmed earnings and revenue guidance for the second
quarter and full year.
Price: $27.09
Net Change: -$4.46
% Change: 14.14% Loss
Volume: 540,269 Shares
... ... ...
USA INTERACTIVE (USAI)
Deutsche Bank has issued an $805 million nine-year
floating rate bond exchangeable into Vivendi Universal's
(V) stake in USA Interactive.
Price: $22.24
Net Change: -$2.02
% Change: 8.31% Loss
Volume: 9.6M Shares
... ... ...
MICROSTRATEGY (MSTR)
Hallmark Cards Inc. chose MicroStrategy Inc.'s platform
as its enterprise standard for business reporting,
analysis and information delivery.
Price: $19.85
Net Change: -$1.04
% Change: 4.98% Loss
Volume: 100,100 Shares
... ... ...
MCDERMOTT (MDR)
Refinanced its credit facilities, allowing for
borrowings and letters of credit up to $180 million.
Price: $4.08
Net Change: $0.51
% Change: 14.29% Gain
Volume: 61,200 Shares
GRMN worth watching
AMAT going positive as they reward the co for such a great report. Give me a break.....
WEBX continues higher.
VIP.....Watch for breakout
Bought SURE
Getting in before the crowd. Yup, Its my feeling that SURE is a perfect candidate for a nice move up soon. We must protect our food and SURE is sitting in a key position. Not only that, take a look at all the recent contracts. These guys are going to kick butt soon.
Headquartered in San Diego, California, SureBeam Corporation is a leading provider of electron beam food safety systems and services for the food industry. SureBeam's technology significantly improves food quality, extends product freshness, and provides disinfestation that helps to protect the environment. The SureBeam patented system is based on proven electron beam and x-ray technology that destroys harmful food-borne bacteria much like thermal pasteurization does to milk. This technology can also eliminate the need for toxic chemical fumigants used in pest control that may be harmful to the earth's ozone layer. For its "great step" into food safety, SureBeam's revolutionary technology is the winner of Food Processing Magazine's "Innovation Award" for 2001. SureBeam is also ranked by Deloitte & Touche as the 37th fastest growing technology company in the Orange County/San Diego region for 2002.
02/10: Weis Markets to Sell SureBeam(R) Processed Fresh Ground Beef Throughout Six Sta
02/05: ShopRite Supermarkets to Sell SureBeam(R) Processed Fresh Ground Beef Throughou
02/04: SureBeam Schedules 2002 Fourth Quarter and Fiscal Year End Earnings Release and
02/04: Stop & Shop Offers SureBeam(R) Processed Fresh Ground Beef to Customers in Nort
02/03: GIANT to Sell SureBeam(R) Processed Fresh Ground Beef Throughout Mid-Atlantic R
01/31: FEATURE-U.S. food industry begins to embrace irradiation
01/29: Safeway to Sell SureBeam(R) Processed Fresh Ground Beef in Baltimore and Washin
01/14: Schnucks First to Introduce SureBeam(R) Processed Fresh Ground Beef in Key Miss
01/13: Giant Eagle First to Sell SureBeam(R) Processed Fresh Ground Beef in Key Pennsy
ID NEWS: More industry acceptance of irradiation?
FEBRUARY 06, 2003 -- Yesterday the Reuters News Service reported that
the U.S. food industry is "stepping up" use of new irradiation technology,
galvanized by the record number of meat recalls last year.
SureBeam Corp., San Diego, which offers electron beam technology as a
means of irradiation, is the major beneficiary of this move toward food safety
treatment. The food safety technology provider says it anticipates
processing up to 350 million pounds of beef this year, as compared with 15
million pounds in 2002.
Furthermore, SureBeam has reached a new milestone in foodservice, with
the announcement that Performance Food Group, Richmond, VA, the
nation's third largest broadliner, will offer customers its own private-label line
of SureBeam-irradiated beef. (For more details, see ID Management Report
lead story, 2/6/03.)
>>>You short the bu$$ or looking for entry? I just extricated myself from the bu$$ here at $12.53 for just $.12 and from CCMP as well at $41.82 for $.12 as well. That was close.
Zeev<<<
I'm short at $13.12 and $13.85. Building a little position here. My stop is at $14. I think the general market is in for something very unexpected like a small crash. Call it intuition. The wind should pull RMBS thru that $13.12 line. We shall see...
May the wind push RMBS south. I think so....
WEBX surging to a day high
Kudlow works for CNBC.
CNBC works for Bush.
KSS ....Watching as a short candidate. See chart
WPI....Watching and want to see it break thru $29.50.
I suppose I should have said more. I like the PRX chart. The stock has been hitting new highs while the market has been weak.
PRX cooking
>>>Have you covered yet? Or do you think it will fall more?
RMBS $13.58 currently.<<<
I'm holding......Shorted the other day at $13.13 and now today at $13.85. I'm building a short position here. Understand that I prefer position trading over day trading. Of course, during these crazy market times I will also day trade.
HAL continues higher. Also upgraded
RMBS....Added to short at $13.85
IMCL ...
NEW YORK -- Shares of ImClone Systems Inc. (IMCL) rose Monday after an analyst predicted positive U.S. trial data related to the company's cancer treatment candidate, Erbitux, and pointed to a U.S. product launch as early as the middle of 2004.
Patrick Mooney, an analyst with Thomas Weisel Partners, upgraded the company to "buy" from "market perform," based on "fading noise" related to the alleged improper trading of ImClone's shares in December 2001, as well the favorable clinical trial and approval timeline he provided for the company's Erbitux drug.
Going for a ride on the "X" train.
U.S. Steel, the second-largest U.S. steelmaker behind Nucor Corp.
his is a weekly ranking by First Call of the highest-rated stocks, based on analyst comments contributed within the past month to First Call's database.
To be included on the list, a company must be rated by at least five analysts.
First Call Consensus Recommendation Scale
1 = Buy
2 = Buy/Hold
3 = Hold
4 = Hold/Sell
5 = Sell
Most Attractive Issues
---- ---------- ------
Latest # Analysts Previous
Consensus Covering Consensus
(RRGB) 1.0 5 1.3
(VERS) 1.1 7 1.2
(SCSS) 1.2 6 1.0
(ALTH) 1.2 6 1.3
(ROG) 1.2 5 1.5
(SPN) 1.2 5 1.5
(RWT) 1.2 5 1.4
(CHGO) 1.2 5 1.5
(CEGE) 1.2 5 1.6
(JCOM) 1.2 5 1.3
(BCGI) 1.2 5 1.6
(SHFL) 1.3 7 1.3
(RESP) 1.3 7 1.4
(FLIR) 1.3 7 1.9
(XOMA) 1.3 6 1.4
(STSA) 1.3 6 1.4
(GRTS) 1.3 6 1.5
(RARE) 1.4 14 1.3
(ACAS) 1.4 10 1.4
(FCN) 1.4 8 1.3
(GTRC) 1.4 8 1.3
(RACN) 1.4 7 1.5
(KROL) 1.4 7 1.0
(MANT) 1.4 7 1.3
(AGP) 1.4 7 1.5
(ESE) 1.4 5 1.2
(BBX) 1.4 5 1.3
(UDI) 1.4 5 1.5
(EME) 1.4 5 1.5
(TYL) 1.4 5 1.3
(XRAY) 1.4 5 1.3
(BGFV) 1.4 5 1.2
(DKS) 1.4 5 1.5
(WSFS) 1.4 5 1.6
(RINO) 1.4 5 1.3
(OIIM) 1.4 5 1.3
(PPDI) 1.5 13 1.5
(MIK) 1.5 13 1.6
(RI) 1.5 12 1.5
(MOVI) 1.5 11 1.6
(COCO) 1.5 10 1.4
(DNR) 1.5 8 1.6
(PLB) 1.5 8 1.6
(TEX) 1.5 6 1.7
(HIBB) 1.5 6 1.3
(AHG) 1.5 6 1.6
(SURE) 1.5 6 1.6
(PII) 1.5 6 1.6
(RLI) 1.5 6 1.4
(FEIC) 1.5 6 2.0
(MLS) 1.5 6 1.4
(HCA) 1.6 28 1.7
(FNM) 1.6 24 1.7
(CIFR) 1.6 18 1.8
(CMX) 1.6 17 1.7
(ADRX) 1.6 15 1.7
(GGP) 1.6 14 1.5
(AGN) 1.6 13 1.7
(WCN) 1.6 11 1.5
(CECO) 1.6 11 2.2
(IRM) 1.6 10 1.9
(UOPX) 1.6 10 1.7
(BMRN) 1.6 10 1.7
(EXBD) 1.6 10 1.7
(IDBE) 1.6 9 1.6
RAH....I like the chart. Will watch
Cover Story 2/17/03
Living Without Oil
As war looms, the search for new energy alternatives is all the more urgent
http://www.usnews.com/usnews/issue/030217/biztech/17oil.htm
Pru's Acampora says lack of fear a negative for stocks
02/10/2003 14:21:12 - By Tomi Kilgore
Ralph Acampora, technical analyst at Prudential Financial, said the market is looking "uglier," as sentiment indicators are still not showing enough fear. Although the CBOE Volatility Index , widely seen as a gauge of investor fear, has been approaching four-month highs, it is still well below levels seen in early October. The "Vix" is currently down 1.5 percent amid rallies in the major market indexes.
Ya....about 60% of the population;)
MDCO closing strong.